AR095982A1 - Factores de transcripción artificiales modificados genéticamente para superar el atrapamiento endosómico - Google Patents
Factores de transcripción artificiales modificados genéticamente para superar el atrapamiento endosómicoInfo
- Publication number
- AR095982A1 AR095982A1 ARP140101460A ARP140101460A AR095982A1 AR 095982 A1 AR095982 A1 AR 095982A1 AR P140101460 A ARP140101460 A AR P140101460A AR P140101460 A ARP140101460 A AR P140101460A AR 095982 A1 AR095982 A1 AR 095982A1
- Authority
- AR
- Argentina
- Prior art keywords
- genetically modified
- overcome
- artificial transcription
- transcription factors
- endosomic
- Prior art date
Links
- 102000040945 Transcription factor Human genes 0.000 title abstract 4
- 108091023040 Transcription factor Proteins 0.000 title abstract 4
- 108090000623 proteins and genes Proteins 0.000 abstract 3
- 101710185494 Zinc finger protein Proteins 0.000 abstract 2
- 102100023597 Zinc finger protein 816 Human genes 0.000 abstract 2
- 230000026683 transduction Effects 0.000 abstract 2
- 238000010361 transduction Methods 0.000 abstract 2
- 108091005804 Peptidases Proteins 0.000 abstract 1
- 239000004365 Protease Substances 0.000 abstract 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 abstract 1
- 108091006088 activator proteins Proteins 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 108091006086 inhibitor proteins Proteins 0.000 abstract 1
- 239000012528 membrane Substances 0.000 abstract 1
- 230000030648 nucleus localization Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
- C07K2319/81—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor containing a Zn-finger domain for DNA binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Ophthalmology & Optometry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Marine Sciences & Fisheries (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Abstract
Factor de transcripción artificial que comprende una proteína con dedos de cinc polidáctil que apunta específicamente a un promotor génico, modificado genéticamente para superar el atrapamiento endosómico después de la transducción en las células. Dicho factor de transcripción artificial que comprende una proteína con dedos de cinc polidáctil fusionado con un dominio proteico inhibidor o activador, una secuencia de localización nuclear, un dominio de transducción de proteínas, y un sitio de reconocimiento de proteasa específico endosómico. Estos factores artificiales de transcripción transducibles son particularmente útiles para el tratamiento de enfermedades causadas o moduladas por proteínas del receptor unidas a membrana, proteínas del receptor nuclear o productos de genes haploinsuficientes. Composición farmacéutica, célula.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13162197 | 2013-04-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR095982A1 true AR095982A1 (es) | 2015-11-25 |
Family
ID=48044672
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP140101460A AR095982A1 (es) | 2013-04-03 | 2014-04-01 | Factores de transcripción artificiales modificados genéticamente para superar el atrapamiento endosómico |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20160046682A1 (es) |
| EP (1) | EP2981547A1 (es) |
| JP (1) | JP2016515595A (es) |
| KR (1) | KR20160002880A (es) |
| CN (1) | CN105339386A (es) |
| AR (1) | AR095982A1 (es) |
| AU (1) | AU2014247130A1 (es) |
| BR (1) | BR112015025283A2 (es) |
| CA (1) | CA2908455A1 (es) |
| EA (1) | EA201591593A1 (es) |
| MA (1) | MA38541A1 (es) |
| MX (1) | MX2015014021A (es) |
| PH (1) | PH12015502421A1 (es) |
| SG (1) | SG11201508057VA (es) |
| TN (1) | TN2015000437A1 (es) |
| TW (1) | TW201514202A (es) |
| WO (1) | WO2014161880A1 (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016050934A1 (en) * | 2014-10-02 | 2016-04-07 | Aliophtha Ag | Endosomal disentanglement of artificial transcription factors |
| US11371023B2 (en) * | 2016-11-22 | 2022-06-28 | Wisconsin Alumni Research Foundation | Artificial transcription factors and uses thereof |
| CN106987599B (zh) * | 2017-03-28 | 2021-06-11 | 重庆医科大学 | 一种抑制人bcr-abl融合基因表达或导致人bcr-abl基因功能丧失的锌指核酸酶及其应用 |
| CN107632160B (zh) * | 2017-08-30 | 2019-04-30 | 福建师范大学 | Celsr3蛋白在制备肝癌术后预后评估试剂盒中的应用、肝癌预后评估试剂盒及方法 |
| CN110108887B (zh) * | 2019-05-05 | 2022-01-28 | 深港产学研基地（北京大学香港科技大学深圳研修院） | Mff在心衰中的应用 |
| CA3138576A1 (en) * | 2019-05-16 | 2020-11-19 | Trustees Of Boston University | Regulated synthetic gene expression systems |
| CN112695052A (zh) * | 2020-12-25 | 2021-04-23 | 华南农业大学 | 一种重组人糖皮质激素受体GRα-His蛋白及其表达和纯化方法 |
| CN113499335B (zh) * | 2021-07-13 | 2023-06-20 | 中国人民解放军军事科学院军事医学研究院 | 一种靶向自噬融合治疗神经退行性疾病的药物 |
| WO2023028598A1 (en) * | 2021-08-26 | 2023-03-02 | Donald Danforth Plant Science Center | Engineering disease resistance by editing the epigenome |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050042603A1 (en) | 2003-07-01 | 2005-02-24 | Allele Biotechnology & Pharmaceuticals, Inc. | Compositions and methods for peptide-assisted transfection |
| WO2008063113A1 (en) | 2006-11-20 | 2008-05-29 | Cepep Iii Ab | Cell -penetrating peptides and constructs containing them consisting 15-25 amino acids of tumor supressor protein p14arf or p19arf |
| US20110318830A1 (en) * | 2008-11-12 | 2011-12-29 | The Regents Of The University Of California | Compositions and methods for re-programming and re-differentiating cells |
| KR101095841B1 (ko) | 2009-02-19 | 2011-12-21 | 주식회사 나이벡 | 표적 선택적 세포／조직 투과기능 활성을 가지는 펩타이드 및 그 용도 |
-
2014
- 2014-04-01 TW TW103112114A patent/TW201514202A/zh unknown
- 2014-04-01 AR ARP140101460A patent/AR095982A1/es unknown
- 2014-04-02 CN CN201480031910.4A patent/CN105339386A/zh active Pending
- 2014-04-02 WO PCT/EP2014/056589 patent/WO2014161880A1/en active Application Filing
- 2014-04-02 US US14/781,701 patent/US20160046682A1/en not_active Abandoned
- 2014-04-02 MX MX2015014021A patent/MX2015014021A/es unknown
- 2014-04-02 EP EP14714289.7A patent/EP2981547A1/en not_active Withdrawn
- 2014-04-02 BR BR112015025283A patent/BR112015025283A2/pt not_active Application Discontinuation
- 2014-04-02 KR KR1020157031592A patent/KR20160002880A/ko not_active Application Discontinuation
- 2014-04-02 JP JP2016505804A patent/JP2016515595A/ja active Pending
- 2014-04-02 EA EA201591593A patent/EA201591593A1/ru unknown
- 2014-04-02 AU AU2014247130A patent/AU2014247130A1/en not_active Abandoned
- 2014-04-02 SG SG11201508057VA patent/SG11201508057VA/en unknown
- 2014-04-02 CA CA2908455A patent/CA2908455A1/en not_active Abandoned
-
2015
- 2015-09-28 TN TN2015000437A patent/TN2015000437A1/en unknown
- 2015-10-20 PH PH12015502421A patent/PH12015502421A1/en unknown
- 2015-10-21 MA MA38541A patent/MA38541A1/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MA38541A1 (fr) | 2017-02-28 |
| JP2016515595A (ja) | 2016-05-30 |
| MX2015014021A (es) | 2016-06-24 |
| EP2981547A1 (en) | 2016-02-10 |
| CA2908455A1 (en) | 2014-10-09 |
| TN2015000437A1 (en) | 2017-01-03 |
| KR20160002880A (ko) | 2016-01-08 |
| PH12015502421A1 (en) | 2016-02-22 |
| EA201591593A1 (ru) | 2016-04-29 |
| US20160046682A1 (en) | 2016-02-18 |
| SG11201508057VA (en) | 2015-10-29 |
| WO2014161880A1 (en) | 2014-10-09 |
| BR112015025283A2 (pt) | 2017-10-10 |
| CN105339386A (zh) | 2016-02-17 |
| AU2014247130A1 (en) | 2015-10-22 |
| TW201514202A (zh) | 2015-04-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR095982A1 (es) | Factores de transcripción artificiales modificados genéticamente para superar el atrapamiento endosómico | |
| CL2016003096A1 (es) | Métodos para cosechar cultivos de células de mamífero | |
| AR103161A1 (es) | Anticuerpos antimiostatina y regiones fc variantes así como métodos de uso | |
| BR112017018919A8 (pt) | Proteínas de fusão imunomoduladoras e seus usos | |
| PE20210451A1 (es) | Oligonucleotidos para inducir la expresion paterna de ube3a | |
| BR112017024384A2 (pt) | bactérias modificadas para reduzir hiperfenilalaninemia | |
| BR112013007862A2 (pt) | ácidos nucleicos manipulados e métodos de uso dos mesmos. | |
| ES2693321T3 (es) | Péptidos antiinflamatorios y composición que comprende los mismos | |
| ES2721309T3 (es) | Composición para preparar tagatosa y método para preparar tagatosa a partir de fructosa | |
| GT201400188A (es) | Biocontrol | |
| EA201692025A1 (ru) | Доставка белков, осуществляемая на основе бактерий | |
| CY1123144T1 (el) | Επαγωγη καρδιακης αναγεννησης μe microrna | |
| CU24405B1 (es) | Proteínas de variantes de secuencias de aminoácidos de cry1da1 activas para lepidópteros | |
| BR112016028512A8 (pt) | método de cultivo de uma célula de mamífero e método de produção de uma proteína recombinante | |
| AR124933A2 (es) | Molécula de ácido nucleico aislada, vector aislado y célula cho aislada y modificada que es incapaz de regenerar en un individuo completo | |
| CL2016001900A1 (es) | Sobreexpresión de los reguladores de caminos de n-glicosilación para regular la glicosilación de proteinas recombinante | |
| CY1124079T1 (el) | Αποτελεσματικη επιλεκτικοτητα των ανασυνδυασμενων πρωτεϊνων | |
| UA113843C2 (xx) | Стійка до бактерій трансгенна рослина, яка містить дисфункціональні білки t3ss | |
| AR095472A1 (es) | Promotores constitutivos de soja | |
| PH12016502024B1 (en) | Tonoplast proton/sugar antiporter proteins and the use thereof to increase the saccharose concentration in a saccharose storage organ of plants | |
| BR112017012389A2 (pt) | supressão de rnai parental de gene kruppel para controlar pragas de coleóptero | |
| BR112018007901A2 (pt) | produção biológica de metacrilato de metila | |
| BR112018005464A2 (pt) | expressão de proteínas contendo fc | |
| BR112018009245A2 (pt) | drimenol sintases iii | |
| TW201613622A (en) | Composition for skincare and pharmaceutical composition and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |